Tissue Heart Valves Global Market Report 2025

The tissue heart valves market size has grown steadily in recent years. It will grow from $1.48 billion in 2024 to $1.53 billion in 2025 at a compound annual growth rate (CAGR) of 3.1%. The growth during the historic period can be attributed to the increasing prevalence of lifestyle diseases, rising healthcare expenditures, a growing elderly population, a surge in cardiac and pathological disorders, and the rising incidence of heart diseases.

The tissue heart valves market size is expected to see steady growth in the next few years. It will grow to $1.7 billion in 2029 at a compound annual growth rate (CAGR) of 2.7%. The projected growth in the forecast period can be attributed to the rising prevalence of cardiovascular diseases, the increasing adoption of sutureless procedures, a growing aging population, higher demand for cardiovascular treatments, and increased healthcare investments. Key trends expected during this period include technological innovations, the development of advanced culture systems, improvements in imaging technologies, advancements in surgical techniques, and the expansion of healthcare markets in emerging regions.

The increasing prevalence of cardiovascular diseases (CVDs) is expected to drive the growth of the tissue heart valves market in the coming years. CVDs, which include conditions such as heart attacks, strokes, and hypertension, are among the leading causes of mortality worldwide. This rise is primarily driven by unhealthy lifestyles, aging populations, increased prevalence of risk factors, poor diets, physical inactivity, smoking, stress, and urbanization, all contributing to higher rates of heart-related disorders. Tissue heart valves play a crucial role in treating cardiovascular diseases by offering a biocompatible, durable, and less thrombogenic solution for patients requiring valve replacement, ultimately improving long-term heart function and reducing complications. For example, in September 2024, a report by the Heart Failure Society of America (HFSA) stated that approximately 6.7 million Americans aged 20 and older are living with heart failure (HF), with projections estimating this number to rise to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. This rising burden of CVDs is fueling the demand for tissue heart valves.

Companies operating in the tissue heart valves market are focusing on technological innovations to improve patient outcomes. For instance, in June 2024, Medtronic plc, an Ireland-based technology company, launched the Avalus Ultra valve, a next-generation surgical aortic tissue valve designed to enhance ease of use during implantation and support long-term patient management. This valve, built on a decade of clinical experience with the Avalus valve, features a low profile, a polyetheretherketone (PEEK) base frame for consistent circularity, and an industry-leading Effective Orifice Area (EOA) to improve blood flow. Additionally, it includes a radiopaque coil for better visibility in future valve-in-valve procedures, ensuring long-term durability for patients with aortic stenosis.

In February 2024, Foldax Inc., a US-based medical device company, partnered with Dolphin Life Science India LLP to manufacture the Tria polymer mitral surgical heart valve in India. This collaboration enables in-country production and distribution, making advanced heart valve solutions more accessible to patients. Dolphin Life Science India LLP is an India-based life sciences company specializing in heart valve manufacturing and distribution.

Major players in the tissue heart valves market are Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Edwards Lifesciences Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, LifeNet Health Inc., TTK Healthcare Ltd., Braile Biomédica, On-X Life Technologies Inc., Anteris Technologies Ltd., Labcor Laboratórios Ltd., CARDION s.r.o., CryoLife Inc., Colibri Heart Valve LLC, Foldax Inc., Balance Medical Technologies Co. Ltd., MiCardia Corporation, Neovasc Inc.

North America was the largest region in the tissue heart valves market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tissue heart valves report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tissue heart valves market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tissue heart valves are biological heart valves used in replacement surgeries, designed to function such as natural heart valves as an alternative to mechanical ones.

The primary types of tissue heart valves are stented and stentless valves. Stented tissue heart valves are bioprosthetic valves reinforced with a metal or polymer frame (stent) to provide structural support and simplify implantation during valve replacement procedures. These valves come in various types, including aortic, mitral, tricuspid, and pulmonary valves. They are utilized by multiple end-users, such as hospitals, ambulatory surgical centers, and other medical facilities.

The tissue heart valves market research report is one of a series of new reports that provides tissue heart valves market statistics, including the tissue heart valves industry global market size, regional shares, competitors with the tissue heart valves market share, detailed tissue heart valves market segments, market trends, and opportunities, and any further data you may need to thrive in the tissue heart valves industry. This tissue heart valves market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tissue heart valves market consists of sales of porcine xenograft valves, bovine pericardial valves, and autograft valves. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.